

**INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL STANDALONE FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS**

**To The Board of Directors of**

**Fermenta Biotech Limited (Formerly known as DIL Limited)**

**Opinion and Conclusion**

We have (a) audited the Standalone Financial Results for the year ended March 31, 2022 and (b) reviewed the Standalone Financial Results for the quarter ended March 31, 2022 (refer Other Matters section below), which were subjected to a limited review by us, both included in the accompanying "Statement of Standalone Financial Results for the Quarter and Year Ended March 31, 2022" of Fermenta Biotech Limited (Formerly known as DIL Limited) ("the Company"), ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

**(a) Opinion on Annual Standalone Financial Results**

In our opinion and to the best of our information and according to the explanations given to us, the Standalone Financial Results for the year ended March 31, 2022:

- i. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- ii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and total comprehensive income and other financial information of the Company for the year then ended.

**(b) Conclusion on Unaudited Standalone Financial Results for the quarter ended March 31, 2022**

With respect to the Standalone Financial Results for the quarter ended March 31, 2022, based on our review conducted as stated in paragraph (b) of Auditor's Responsibilities section below, nothing has come to our attention that causes us to believe that the Standalone Financial Results for the quarter ended March 31, 2022, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

*QRC*

**Basis for Opinion on the Audited Standalone Financial Results for the year ended March 31, 2022**

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("the ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results for the year ended March 31, 2022 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

**Management's Responsibilities for the Statement**

This Statement which includes the Standalone Financial Results is the responsibility of the Company's Board of Directors and has been approved by them for the issuance. The Standalone Financial Results for the year ended March 31, 2022 has been compiled from the related audited standalone financial statements. This responsibility includes the preparation and presentation of the Standalone Financial Results for the quarter and year ended March 31, 2022 that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the Company.

*Q RKG*

**Auditor's Responsibilities**

**(a) Audit of the Standalone Financial Results for the year ended March 31, 2022**

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results for the year ended March 31, 2022 as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Standalone Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

*D RCB*

**Deloitte  
Haskins & Sells LLP**

- Evaluate the overall presentation, structure and content of the Annual Standalone Financial Results, including the disclosures, and whether the Annual Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Results of the Company to express an opinion on the Annual Standalone Financial Results.

Materiality is the magnitude of misstatements in the Annual Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

**(b) Review of the Standalone Financial Results for the quarter ended March 31, 2022**

We conducted our review of the Standalone Financial Results for the quarter ended March 31, 2022 in accordance with the Standard on Review Engagements ("SRE") 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

*D RKB*

**Other Matters**

- The Statement includes the results for the Quarter ended March 31, 2022 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subjected to a limited review by us. Our report on the Statement is not modified in respect of this matter.

For DELOITTE HASKINS & SELLS LLP  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)



Rajesh K. Hiranandani  
Partner  
(Membership No. 36920)  
(UDIN: 22036920AJWCTZ1327)



Place: Thane  
Date: May 30, 2022



Fermenta Biotech Limited (Formerly Known as DIL Limited)

CIN:L99999MH1951PLC008485

Regd. Office: A-1501, Thane One, DIL Complex, Ghodbunder Road, Majiwada, Thane (West) 400 610, Maharashtra, India.

Tel:+91-22-67980888, Fax:+91-22-67980999, Email: info@fermentabiotech.com, Website: www.fermentabiotech.com

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2022							(₹ in Lakhs)
Sr.N o.	Particulars	Standalone					Audited Year Ended
		Quarter Ended		Unaudited		Audited	
		Unaudited	December 31,	March 31,	March 31,		
		2022	2021	2021	2022	2021	2021
		[Refer Note 10]					
1	Income						
	a) Revenue from operations	9,465.96	8,540.78	9,090.33	38,796.06		37,282.15
	b) Other income	297.11	113.15	374.35	752.62		661.81
2	Total Income (a+b)	9,763.07	8,653.93	9,464.68	39,548.68		37,943.96
3	Expenses						
	a) Cost of materials consumed	3,630.58	2,382.61	3,757.71	13,312.90		13,883.49
	b) Purchases of stock-in-trade	135.82	69.78	42.72	341.84		68.31
	c) Change in inventories of finished goods, stock-in-trade and work-in-progress	(60.97)	581.85	(629.12)	764.71		(1,587.56)
	d) Employee benefits expense	1,136.31	1,605.69	1,357.04	5,936.02		5,749.88
	e) Finance costs	447.72	412.46	501.93	1,722.60		1,807.48
	f) Depreciation and amortisation expense	602.76	620.95	594.23	2,367.41		1,903.14
	g) Commission on sales	72.47	29.30	68.99	196.20		758.68
	h) Other expenses	2,697.16	2,644.24	2,686.99	10,650.76		9,037.64
4	Total expenses (a to h)	8,661.85	8,346.88	8,380.49	35,292.44		31,621.06
5	Profit before tax (2-3)	1,101.22	307.05	1,084.19	4,256.24		6,322.90
	Tax expense						
	a) Current tax	189.51	53.98	188.44	740.75		1,125.79
	b) Deferred tax charge/(credit)	5.00	71.34	(70.82)	491.76		0.26
6	Total tax expense (a+b)	194.51	125.32	117.62	1,232.51		1,126.05
7	Profit for the period after tax (4-5)	906.71	181.73	966.57	3,023.73		5,196.85
7	Other Comprehensive Income						
(A)	i) Items that will not be reclassified to Profit or Loss	(35.76)	(1.47)	(6.18)	(29.53)		(5.76)
(B)	ii) Income tax thereon	9.70	-	1.49	9.70		1.49
	Items that will be reclassified to Profit or Loss						
8	Total other comprehensive income/(Loss) (A+B)	(26.06)	(1.47)	(4.69)	(19.83)		(4.27)
9	Total Comprehensive Income for the period/year (6+7)	880.65	180.26	961.88	3,003.90		5,192.58
9	Paid-up equity share capital (Face value ₹ 5/- per share) - 2,88,47,322 number of equity shares	1,442.37	1,442.37	1,442.37	1,442.37		1,442.37
10	Earnings per equity share of ₹ 5 each (not annualised)						
	a) ₹ Basic	3.14	0.63	3.35	10.48		18.02
	b) ₹ Diluted	3.14	0.63	3.35	10.43		17.92

See accompanying notes to the Standalone financial results

## Notes

1 Balance Sheet as at		₹ in Lakhs	
PARTICULARS		Standalone	
		March 31, 2022	March 31, 2021
		Audited	Audited
<b>ASSETS</b>			
1	<b>Non-current assets</b>		
	(a) Property, plant and equipment	19,346.87	15,375.65
	(b) Capital work-in-progress	2,989.35	5,270.11
	(c) Right of use assets	1,571.27	1,471.82
	(d) Investment property	6,678.63	6,820.29
	(e) Goodwill	411.65	411.65
	(f) Other Intangible assets	667.95	877.44
	(g) Intangible assets under development	467.16	420.55
	(h) Investments		
	i) Investments in subsidiaries	1,270.02	1,270.02
	ii) Investments in an associate	-	-
	(i) Financial assets		
	i) Investments	28.71	24.94
	ii) Share application money	-	-
	iii) Loans	643.11	1.85
	iv) Others financial assets	669.16	219.25
	(j) Deferred tax assets (net)	3,329.12	3,811.18
	(k) Non-current tax assets (net)	1,316.57	1,129.52
	(l) Other non-current assets	350.31	353.25
	Sub-total - Non-current assets	39,739.88	37,457.52
2	<b>Current assets</b>		
	(a) Inventories	12,957.95	13,279.27
	(b) Financial assets		
	i) Trade receivables	11,782.62	9,611.96
	ii) Cash and cash equivalents	1,019.22	1,356.57
	iii) Bank balances other than (ii) above	2,055.31	2,773.80
	iv) Loans	1.50	476.60
	v) Other financial assets	507.18	795.01
	(c) Other current assets	3,200.97	2,503.05
	Sub-total - Current assets	31,524.75	30,796.26
	<b>TOTAL ASSETS</b>	71,264.63	68,253.78
<b>EQUITY AND LIABILITIES</b>			
1	<b>EQUITY</b>		
	(a) Equity Share capital	1,442.37	1,442.37
	(b) Other Equity	38,154.82	35,602.45
	Total Equity	39,597.19	37,044.82
2	<b>Non-current liabilities</b>		
	(a) Financial liabilities		
	i) Borrowings	11,468.25	11,043.80
	ii) Lease liabilities	371.77	349.01
	iii) Other financial liabilities	72.43	47.82
	(b) Provisions	564.83	449.20
	(c) Other non-current liabilities	524.43	34.04
	Sub-total - Non-current liabilities	13,001.71	11,923.87
3	<b>Current liabilities</b>		
	(a) Financial Liabilities		
	i) Borrowings	12,146.34	11,888.59
	ii) Lease liabilities	107.28	116.46
	iii) Trade payables		
	-Total outstanding dues of micro and small enterprises and;	224.72	78.34
	-Total outstanding dues of creditors other than micro enterprises and small enterprises	4,331.92	4,491.51
	iv) Other financial liabilities	1,275.59	1,844.71
	(b) Other current liabilities	469.81	758.60
	(c) Provisions	78.06	74.87
	(d) Current tax liabilities (Net)	32.01	32.01
	Sub-total - Current liabilities	18,665.73	19,285.09
	<b>TOTAL EQUITY AND LIABILITIES</b>	71,264.63	68,253.78

Q PKG

①

## NOTES:

2 Segment Information		Standalone				(₹. in Lakhs)	
Particulars	Quarter ended			Year Ended			
	Unaudited March 31, 2022	Unaudited December 31, 2021	Unaudited March 31, 2021	Audited March 31, 2022	Audited March 31, 2021		
	[Refer Note 10]		[Refer Note 10]				
Segment revenue							
- Bulk drugs/chemicals	9,083.84	8,147.12	8,655.51	37,172.11	35,537.24		
- Property	382.11	393.67	434.82	1,623.95	1,744.91		
- Unallocated	297.12	113.14	374.35	752.62	661.81		
Total	9,763.07	8,653.93	9,464.68	39,548.68	37,943.96		
Less : Inter-segment revenue	-	-	-	-	-		
Total Income	9,763.07	8,653.93	9,464.68	39,548.68	37,943.96		
Segment results							
- Bulk drugs/chemicals	1,320.46	731.14	983.60	5,355.66	7,028.44		
- Property	71.04	176.91	208.35	649.55	924.48		
- Unallocated (Net)	157.44	(188.54)	394.17	(26.37)	177.46		
Total	1,548.94	719.51	1,586.12	5,978.84	8,130.38		
Inter-segment results							
Total Profit before tax and before finance cost	1,548.94	719.51	1,586.12	5,978.84	8,130.38		
Less : Finance costs	(447.72)	(412.46)	(501.93)	(1,722.60)	(1,807.48)		
Total Profit before tax	1,101.22	307.05	1,084.19	4,256.24	6,322.90		
Segment Assets							
- Bulk Drugs/chemicals	53,170.71	51,784.09	48,292.31	53,170.71	48,292.31		
- Property	7,021.08	7,271.44	7,496.72	7,021.08	7,496.72		
- Unallocated	11,072.84	11,190.66	12,464.75	11,072.84	12,464.75		
Total Segment Assets	71,264.63	70,246.19	68,253.78	71,264.63	68,253.78		
Segment Liabilities							
- Bulk Drugs/chemicals	6,094.59	6,489.04	6,824.54	6,094.59	6,824.54		
- Property	1,507.18	849.69	802.95	1,507.18	802.95		
- Unallocated	24,065.67	24,002.75	23,581.47	24,065.67	23,581.47		
Total Segment Liabilities	31,667.44	31,341.48	31,208.96	31,667.44	31,208.96		



3 Statement of Cash Flows		(₹ in Lakhs)	
Particulars	Standalone		
	Year Ended		
	Audited	Audited	
	March 31, 2022	March 31, 2021	
<b>A) CASH FLOWS FROM OPERATING ACTIVITIES</b>			
Profit before tax	4,256.24	6,322.90	
Adjustments for:			
Depreciation and amortisation expense	2,367.41	1,903.14	
Net unrealised foreign exchange (gain)	(51.10)	(206.32)	
Loss on sale/write off, of property, plant and equipment (Net)	2.67	16.03	
Allowance for doubtful debts	32.85	118.96	
Share based payments to employees	269.65	592.05	
Finance costs	1,722.60	1,807.48	
Interest income	(141.66)	(354.61)	
Dividend income	-	(0.58)	
Liabilities / provisions no longer required written back	(223.94)	(54.21)	
Trade receivables and advances written off	3.44	90.96	
Net (gain)/Loss on fair value changes of derivatives measured at FVTPL	(86.58)	110.15	
<b>Operating Profit before working capital changes</b>	<b>8,151.58</b>	<b>10,345.95</b>	
Movements in working capital:			
(Increase) in trade receivables	(1,856.39)	(1,561.90)	
Decrease/(increase) in inventories	321.32	(1,924.84)	
(Increase)/decrease in other assets	(582.62)	127.50	
Increase/(decrease) in trade payables	186.63	(59.27)	
Increase in provisions	85.51	57.37	
(Increase)/decrease in other liabilities	(337.20)	659.67	
	<b>5,968.83</b>	<b>7,644.48</b>	
Income taxes paid	(927.80)	(1,348.73)	
<b>Net cash generated from operations (A)</b>	<b>5,041.03</b>	<b>6,295.75</b>	
<b>B) CASH FLOWS FROM INVESTING ACTIVITIES</b>			
Payments for purchase of property, plant and equipment, investment property, capital work-in-progress, intangible assets and intangible assets under development	(3,712.83)	(5,491.96)	
Proceeds on sale of property, plant and equipment	9.08	1.32	
Intercompany deposits received back	476.10	1,655.00	
Interest received	235.84	478.80	
Loan given to a subsidiary	(642.26)	-	
Purchase of investments in a subsidiary	-	(1,184.72)	
Dividend received	-	0.58	
Deposits (placed with)/ received back from a financial institution (net)	(50.93)	400.00	
Deposits received back from /(placed with) banks not considered as cash and cash equivalents (net)	438.98	(219.70)	
<b>Net cash used in investing activities (B)</b>	<b>(3,246.02)</b>	<b>(4,360.68)</b>	
<b>C) CASH FLOWS FROM FINANCING ACTIVITIES</b>			
Proceeds from long term borrowings	2,430.46	2,916.54	
Repayment of long term borrowings	(2,122.99)	(1,500.49)	
Net Increase in short term borrowings	59.72	358.46	
Finance costs	(1,667.44)	(1,753.43)	
Repayment of Lease Liabilities	(154.58)	(153.41)	
Dividends paid	(721.18)	-	
<b>Net cash (used in) financing activities (C)</b>	<b>(2,176.01)</b>	<b>(132.33)</b>	
<b>Net increase/(decrease) in cash and cash equivalents (A)+(B)+(C)</b>	<b>(381.00)</b>	<b>1,802.74</b>	
Cash and cash equivalents at the beginning of the year	(93.74)	(1,896.48)	
<b>Cash and cash equivalents at the end of the year</b>	<b>(474.74)</b>	<b>(93.74)</b>	
<b>Components of cash and cash equivalents</b>			
Cash on hand	7.05	4.77	
Balances with banks			
In current accounts	898.77	1,022.65	
In deposit accounts with original maturity for less than 3 months	113.40	329.15	
<b>Cash and cash equivalents</b>	<b>1,019.22</b>	<b>1,356.57</b>	
Bank overdraft/Cash credit facilities	(1,493.96)	(1,450.31)	
<b>Total cash and cash equivalents considered for cash flows</b>	<b>(474.74)</b>	<b>(93.74)</b>	

QPKK-10

- 4 The above standalone financial results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on May 30, 2022. The statutory auditor have carried out an audit of financial results for the year ended March 31, 2022 and a limited review of the financial results of the Company for the quarter ended March 31, 2022. The results of the Company are available for investors at [www.fermentabiotech.com](http://www.fermentabiotech.com) and [www.bseindia.com](http://www.bseindia.com).
- 5 These financial results have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules 2015 (as amended) ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- 6 As per the current assessment of the situation based on the internal and external information available up to the date of approval of these standalone financial results by the Board of Directors, the Company believes that the impact of Covid-19 on its business, assets, internal financial controls, profitability and liquidity, both present and future, would be limited. The eventual outcome of the impact of the global health pandemic may be different from those-estimated as on the date of approval of these standalone financial results and the Company will closely monitor any material changes to the economic environment and their impact on its business in the times to come.
- 7 The date of implementation of the Code on Wages 2019 and the Code on Social Security, 2020 is yet to be notified by the Government. The Company will assess the impact of these Codes and give effect in these financial results when the Rules/Schemes thereunder are notified.
- 8 The Board of Directors in its meeting held on January 31, 2022, approved the Composite Scheme of Amalgamation and Arrangement amongst DVK Investments Private Limited (Holding Company) and Aegean Properties Limited (Wholly owned subsidiary) with the Company in suppression of its earlier resolution passed on October 11, 2021. The Company has submitted its applications to Bombay Stock Exchange.
- 9 The accumulated losses at ₹ 1,709.92 lakhs (including loss of ₹ 193.58 lakhs for the quarter and ₹ 1,300.38 lakhs for the year ended March 31, 2022, respectively) in Fermenta Biotech GmbH, wholly owned subsidiary (WOS) of the Company at Germany exceed the equity share capital and the Company's investment at ₹ 19.33 lakhs. Further, the Company has trade receivables of ₹ 2,722.31 lakhs and expenses recoverable of Rs 462.74 lakhs from this WOS as at March 31, 2022. The WOS was incorporated fairly recently on June 14, 2019 and there has been considerable delay in obtaining the required approvals to execute sales for procedural reasons in view of the global pandemic "Covid-19". The WOS had obtained the required approvals in the previous quarter, and commenced sales of its products. The management of the Company is of the view that these losses have been incurred in view of the unusual circumstances explained and are temporary in nature. The WOS expects to gradually recoup the losses and be in a position to repay its dues to the Company.
- 10 The figures for the quarter ended March 31, 2022 and March 31, 2021 are the balancing figures between the audited figures in respect of the full financial year ended March 31, 2022 and March 31, 2021 and the unaudited published year to date figures upto the nine months ended December 31, 2021 and December 31, 2020 of the relevant financial year which were subjected to a limited review by the statutory auditors.
- 11 The Board of Directors at their meeting held on May 30, 2022 have proposed a dividend of 25 % ( ₹ 1.25 per share) for the financial year ended 2021-2022. The payment of dividend is subject to approval of shareholders in the ensuing Annual General Meeting.

Place: Thane  
May 30, 2022

  
Krishna Datla  
Executive-Vice Chairman

 

**INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL CONSOLIDATED  
FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF**

**Fermenta Biotech Limited (Formerly known as DIL Limited)**

**Opinion and Conclusion**

We have (a) audited the Consolidated Financial Results for the year ended March 31, 2022 and (b) reviewed the Consolidated Financial Results for the quarter ended March 31, 2022 (refer paragraph (a) of Other Matters section below), which were subjected to a limited review by us, both included in the accompanying "Statement of Consolidated Financial Results for the Quarter and Year Ended March 31, 2022" of Fermenta Biotech Limited (Formerly known as DIL Limited) ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income/ loss of its associate for the quarter and year ended March 31, 2022, ("the Statement") being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

**(a) Opinion on Annual Consolidated Financial Results**

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the audit reports of the other auditors on separate financial statements of the subsidiaries referred to in paragraph (b) of Other Matters section below, the Consolidated Financial Results for the year ended March 31, 2022:

(i) includes the results of the following entities:

**Parent**

1. Fermenta Biotech Limited (Formerly known as DIL Limited)

**Subsidiaries**

2. Aegean Properties Limited
3. CC Square Films Limited (Struck off w.e.f. November 2021)
4. G. I. Biotech Private Limited
5. Fermenta Biotech (UK) Limited
6. Fermenta Biotech GmbH
7. Fermenta Biotech USA LLC
8. Fermenta USA LLC

**Associate**

9. Health and Wellness India Private Limited

- (i) is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- (ii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the consolidated net profit and consolidated total comprehensive income and other financial information of the Group for the year ended March 31, 2022.

**(a) Conclusion on Unaudited Consolidated Financial Results for the quarter ended March 31, 2022**

With respect to the Consolidated Financial Results for the quarter ended March 31, 2022, based on our review conducted and procedures performed as stated in paragraph (b) of Auditor's Responsibilities section below and based on the consideration of the review reports of the other auditors referred to in paragraph (b) of Other Matters section below, nothing has come to our attention that causes us to believe that the Consolidated Financial Results for the quarter ended March 31, 2022, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**Basis for Opinion on the Audited Consolidated Financial Results for the year ended March 31, 2022**

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Group and its associate in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("the ICAI") together with the ethical requirements that are relevant to our audit of the Consolidated Financial Results for the year ended March 31, 2022 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us and the audit evidence obtained by the other auditors in terms of their reports referred to in paragraph (b) of Other Matters section below, is sufficient and appropriate to provide a basis for our audit opinion.



**Management's Responsibilities for the Statement**

This Statement, which includes the Consolidated Financial Results, is the responsibility of the Parent's Board of Directors and has been approved by them for the issuance. The Consolidated Financial Results for the year ended March 31, 2022 has been compiled from the related audited consolidated financial statements. This responsibility includes the preparation and presentation of the Consolidated Financial Results for the quarter and year ended March 31, 2022 that give a true and fair view of the consolidated net profit and consolidated other comprehensive income and other financial information of the Group including its associate in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

The respective Board of Directors of the companies included in the Group and of its associate are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and its associate and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the respective financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of this Consolidated Financial Results by the Directors of the Parent, as aforesaid.

In preparing the Consolidated Financial Results, the respective Board of Directors of the companies included in the Group and of its associate are responsible for assessing the ability of the respective entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate their respective entities or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group and of its associate are responsible for overseeing the financial reporting process of the Group and of its associate.

**Auditor's Responsibilities**

**(a) Audit of the Consolidated Financial Results for the year ended March 31, 2022**

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results for the year ended March 31, 2022, as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Consolidated Financial Results.

*ORC*

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Consolidated Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associate to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associate to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Consolidated Financial Results, including the disclosures, and whether the Annual Consolidated Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Perform procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations to the extent applicable.
- Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Results/ Financial Information of the entities within the Group and its associate to express an opinion on the Annual Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entity included in the Annual Consolidated Financial Results of which we are the independent auditors. For the other entities included in the Annual Consolidated Financial Results, which have been audited by the other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

*Q RKG*

Materiality is the magnitude of misstatements in the Annual Consolidated Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Consolidated Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Consolidated Financial Results.

We communicate with those charged with governance of the Parent included in the Consolidated Financial Results where we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

**(b) Review of the Consolidated Financial Results for the quarter ended March 31, 2022**

We conducted our review of the Consolidated Financial Results for the quarter ended March 31, 2022, in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

The Statement includes the results of the entities as listed under paragraph (a)(i) of Opinion and Conclusion section above.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

**Other Matters**

- a) The Statement includes the results for the Quarter ended March 31, 2022, being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subjected to a limited review by us. Our report is not modified in respect of this matter.



b) We did not audit the financial statements of 5 subsidiaries included in the consolidated financial results, whose financial statements reflect total assets of Rs. 6,539.74 Lakhs as at March 31, 2022, and total revenues of Rs. 1555.88 Lakhs and Rs. 4,465.56 Lakhs for the quarter and year ended March 31, 2022, respectively, total net loss after tax of Rs. 208.99 Lakhs and Rs. 1454.66 Lakhs for the quarter and year ended March 31, 2022, respectively and total comprehensive loss (net) of Rs. 208.99 Lakhs and Rs. 1,454.66 Lakhs for the quarter and year ended March 31, 2022, respectively and net cash outflows of Rs. 41.50 Lakhs for the year ended March 31, 2022, as considered in the Statement. The above figures are before giving effect of any consolidation adjustments. These financial statements have been audited/reviewed, as applicable, by other auditors whose reports have been furnished to us by the Management of the Parent and our opinion and conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated under Auditor's Responsibilities section above.

Our report on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors.

c) The consolidated financial results include the unaudited financial information of 2 subsidiaries, whose financial information reflect total assets of Rs. 40.16 Lakhs as at March 31, 2022, and total revenues of Rs. Nil, both, for the quarter and year ended March 31, 2022, total loss after tax of Rs. 1.55 Lakhs and Rs. 1.69 Lakhs for the quarter and year ended March 31, 2022, respectively and total comprehensive loss of Rs. 1.55 Lakhs and Rs. 1.69 Lakhs for the quarter and year ended March 31, 2022, respectively and net cash outflows of Rs. 0.06 Lakhs for the year ended March 31, 2022, as considered in the Statement. The consolidated financial results also includes the Group's share of profit after tax of Rs. Nil and total comprehensive income of Rs. Nil, both, for the quarter and year ended March 31, 2022, as considered in the Statement, in respect of an associate, whose financial information have not been audited by us. The above figures are before giving effect of any consolidation adjustments. These financial information are unaudited and have been furnished to us by the Management of the Parent and our opinion and conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and an associate, is based solely on such unaudited financial information. In our opinion and according to the information and explanations given to us by the Parent's Board of Directors, these financial information are not material to the Group.

Our report on the Statement is not modified in respect of the above matter with respect to our reliance on the financial information certified by the Parent's Board of the Directors.

For DELOITTE HASKINS & SELLS LLP  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)



Rajesh K. Hiranandani  
Partner  
(Membership No. 36920)  
(UDIN: 22036920AJWKPR4811)

Place: Thane  
Date: May 30, 2022







## Notes

1 Balance Sheet as at		₹ in Lakhs	
PARTICULARS		Consolidated	
		March 31, 2022 Audited	March 31, 2021 Audited
	<b>ASSETS</b>		
1	<b>Non-current assets</b>		
	(a) Property, plant and equipment	19,347.38	15,378.50
	(b) Capital work-in-progress	2,989.34	5,270.11
	(c) Right of use assets	1,395.97	1,292.55
	(d) Investment property	6,727.63	6,870.38
	(e) Goodwill	1,095.45	1,071.35
	(f) Other Intangible assets	1,292.36	1,680.35
	(g) Intangible assets under development	467.16	420.55
	(h) Investments		
	Investments in an associate	-	-
	(i) Financial assets		
	i) Investments	28.71	24.94
	ii) Share application money	-	-
	iii) Loans	0.85	1.85
	iv) Others financial assets	669.16	219.25
	(j) Deferred tax assets (net)	3,599.43	4,031.01
	(k) Non-current tax assets (net)	1,318.51	1,131.38
	(l) Other non-current assets	350.31	353.25
	Sub-total - Non-current assets	<b>39,282.26</b>	<b>37,745.47</b>
2	<b>Current assets</b>		
	(a) Inventories	15,947.65	16,227.05
	(b) Financial assets		
	i) Trade receivables	8,709.01	6,801.48
	ii) Cash and cash equivalents	1,305.61	1,679.44
	iii) Bank balances other than (ii) above	2,055.31	2,773.80
	iv) Loans	1.50	476.60
	v) Other financial assets	27.71	347.83
	(c) Other current assets	3,355.20	2,655.95
	Sub-total - Current assets	<b>31,401.99</b>	<b>30,962.15</b>
	<b>TOTAL ASSETS</b>	<b>70,684.25</b>	<b>68,707.62</b>
	<b>EQUITY AND LIABILITIES</b>		
1	<b>EQUITY</b>		
	(a) Equity Share capital	1,442.37	1,442.37
	(b) Other Equity	35,771.10	34,616.65
	Equity attributable to the owners of the Company	<b>37,213.47</b>	<b>36,059.02</b>
	(c) Non-controlling interests	(68.28)	(29.63)
	Total Equity	<b>37,145.19</b>	<b>36,029.39</b>
2	<b>Non-current liabilities</b>		
	(a) Financial liabilities		
	i) Borrowings	11,468.25	11,043.80
	ii) Lease liabilities	196.78	170.02
	iii) Other financial liabilities	72.43	47.82
	(b) Provisions	564.83	449.20
	(c) Other non-current liabilities	524.43	34.04
	Sub-total - Non-current liabilities	<b>12,826.72</b>	<b>11,744.88</b>
3	<b>Current liabilities</b>		
	(a) Financial Liabilities		
	i) Borrowings	12,146.34	11,888.58
	ii) Lease liabilities	106.98	116.19
	iii) Trade payables		
	-Total outstanding dues of micro and small enterprises and;	224.72	78.34
	-Total outstanding dues of creditors other than micro enterprises and small enterprises	6,233.25	6,135.37
	iv) Other financial liabilities	1,275.62	1,844.71
	(b) Other current liabilities	590.38	770.33
	(c) Provisions	103.04	67.82
	(d) Current tax liabilities (Net)	32.01	32.01
	Sub-total - Current liabilities	<b>20,712.34</b>	<b>20,933.35</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>70,684.25</b>	<b>68,707.62</b>

Q RCh (h)

## NOTES:

Particulars	Consolidated						(₹. in Lakhs)
	2 Segment Information		Quarter ended		Year Ended		
	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Audited	
	March 31, 2022	March 31, 2021	December 31, 2021	March 31, 2021	March 31, 2022	March 31, 2021	
	[Refer Note 10]				[Refer Note 10]		
Segment revenue	9,233.75		8,892.43	9,439.88	38,227.62	35,983.97	
- Bulk drugs/chemicals	386.62		398.17	439.32	1,641.95	1,762.91	
- Property	288.03		116.66	537.20	813.59	825.05	
Total	9,908.40		9,407.26	10,416.40	40,683.16	38,571.93	
Less : Inter-segment revenue	4.50		4.50	4.50	18.00	18.00	
Total Income	9,903.90		9,402.76	10,411.90	40,665.16	38,553.93	
Segment results	1,188.51		(319.66)	234.38	3,790.48	5,857.16	
- Bulk drugs/chemicals	93.62		176.87	211.52	661.51	924.24	
- Property	132.80		(188.54)	394.12	(50.96)	177.41	
Total	1,414.93		(331.33)	840.02	4,401.03	6,958.81	
Inter-segment results	0.43		0.42	0.43	1.71	1.71	
Total Profit/(Loss) before tax and before finance cost	1,415.36		(330.91)	840.45	4,402.74	6,960.52	
Less : Finance costs	(443.11)		(409.89)	(502.41)	(1,708.43)	(1,797.46)	
Total Profit/(Loss) before tax	972.25		(740.80)	338.04	2,694.31	5,163.06	
Segment Assets	52,350.82		51,342.50	48,505.21	52,350.82	48,505.21	
- Bulk Drugs/chemicals	7,071.91		7,321.16	7,548.25	7,071.91	7,548.25	
- Property	11,261.52		11,379.81	12,654.16	11,261.52	12,654.16	
Total Segment Assets	70,684.25		70,043.47	68,707.62	70,684.25	68,707.62	
Segment Liabilities	8,222.00		9,543.08	8,570.50	8,222.00	8,570.50	
- Bulk Drugs/chemicals	1,507.61		847.86	803.18	1,507.61	803.18	
- Property	23,809.45		23,087.04	23,304.55	23,809.45	23,304.55	
Total Segment Liabilities	33,539.06		33,477.98	32,678.23	33,539.06	32,678.23	

3 Statement of Cash Flows		(₹ in Lakhs)	
Particulars		Consolidated	
		Year Ended	
		Audited March 31, 2022	Audited March 31, 2021
<b>A) CASH FLOWS FROM OPERATING ACTIVITIES</b>			
Profit before tax		2,694.31	5,163.06
Adjustments for:			
Depreciation and amortisation expense		2,556.16	2,030.84
Net unrealised foreign exchange (gain)		(52.14)	(226.06)
Loss on sale/write off, of property, plant and equipment (Net)		2.67	16.03
Allowance for doubtful debts		141.25	118.96
Share based payments to employees		269.65	592.05
Finance costs		1,708.43	1,797.46
Interest income		(131.63)	(354.61)
Dividend income		-	(0.58)
Liabilities / provisions no longer required written back		(220.84)	(214.20)
Trade receivables and advances written off		3.44	90.96
Net (gain)/Loss on fair value changes of derivatives measured at FVTPL		(86.58)	110.15
<b>Operating Profit before working capital changes</b>		<b>6,884.72</b>	<b>9,124.06</b>
Movements in working capital:			
(Increase)/decrease in trade receivables		(1,701.66)	646.07
Decrease/(increase) in inventories		279.40	(1,916.60)
(Increase) in other assets		(584.31)	(215.25)
Increase/(decrease) in trade payables		441.00	(752.50)
Increase in provisions		184.15	57.37
(Increase)/decrease in other liabilities		(228.35)	668.73
		<b>5,274.95</b>	<b>7,611.88</b>
Income taxes paid		(930.84)	(1,352.16)
<b>Net cash generated from operations (A)</b>		<b>4,344.11</b>	<b>6,259.72</b>
<b>B) CASH FLOWS FROM INVESTING ACTIVITIES</b>			
Payments for purchase of property, plant and equipment, investment property, capital work-in-progress, intangible assets and intangible assets under development		(3,712.82)	(5,527.09)
Proceeds on sale of property, plant and equipment		9.08	1.27
Intercompany deposits received back		476.10	1,655.00
Interest received		235.83	478.81
Acquisition of a subsidiary		-	(943.85)
Dividend received		-	0.58
Deposits (placed with)/ received back from a financial institution (net)		(50.93)	400.00
Deposits received back from /(placed with) banks not considered as cash and cash equivalents (net)		438.98	(219.70)
<b>Net cash used in investing activities (B)</b>		<b>(2,603.76)</b>	<b>(4,154.98)</b>
<b>C) CASH FLOWS FROM FINANCING ACTIVITIES</b>			
Proceeds from long term borrowings		2,430.46	2,916.54
Repayment of long term borrowings		(2,122.99)	(1,500.50)
Net Increase in short term borrowings		59.72	358.46
Finance costs		(1,667.27)	(1,753.42)
Repayment of Lease Liabilities		(136.57)	(135.40)
Dividends paid		(721.18)	-
<b>Net cash (used in) financing activities (C)</b>		<b>(2,157.83)</b>	<b>(114.32)</b>
<b>Net increase/(decrease) in cash and cash equivalents (A)+(B)+(C)</b>		<b>(417.48)</b>	<b>1,990.42</b>
Cash and cash equivalents taken over on acquisition of a subsidiary		-	61.15
Cash and cash equivalents at the beginning of the year		229.13	(1,822.44)
Cash and cash equivalents at the end of the year		(188.35)	229.13
<b>Components of cash and cash equivalents</b>			
Cash on hand		7.05	4.77
Balances with banks			
In current accounts		1,185.16	1,345.52
In deposit accounts with original maturity for less than 3 months		113.40	329.15
Cash and cash equivalents		<b>1,305.61</b>	<b>1,679.44</b>
Bank overdraft/Cash credit facilities		(1,493.96)	(1,450.31)
<b>Total cash and cash equivalents considered for cash flows</b>		<b>(188.35)</b>	<b>229.13</b>

*Q RRB (2)*

- 4 The above consolidated financial results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on May 30, 2022. The statutory auditor have carried out an audit of financial results for the year ended March 31, 2022 and a limited review of the financial results of the Company for the quarter ended March 31, 2022. The results of the Company are available for investors at [www.fermentabiotech.com](http://www.fermentabiotech.com) and [www.bseindia.com](http://www.bseindia.com).
- 5 These financial results have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules 2015 (as amended) ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). The consolidated financial results of the Parent Company, its wholly owned subsidiaries and a step-down subsidiary ("the Group") have been prepared by applying Ind AS 110 on Consolidated Financial Statements.
- 6 As per the current assessment of the situation based on the internal and external information available up to the date of approval of these consolidated financial results by the Parent Board of Directors, the Group believes that the Impact of Covid-19 on its business, assets, internal financial controls, profitability and liquidity, both present and future, would be limited. The eventual outcome of the impact of the global health pandemic may be different from those-estimated as on the date of approval of these consolidated financial results and the Group will closely monitor any material changes to the economic environment and their impact on its business in the times to come.
- 7 The date of implementation of the Code on Wages 2019 and the Code on Social Security, 2020 is yet to be notified by the Government. The Parent Company will assess the impact of these Codes and give effect in these unaudited consolidated financial results when the Rules/Schemes thereunder are notified.
- 8 The Parent Board of Directors in its meeting held on January 31, 2022, approved the Composite Scheme of Amalgamation and Arrangement amongst DVK Investments Private Limited (Holding Company) and Aegean Properties Limited (Wholly owned subsidiary) with the Company in suppression of its earlier resolution passed on October 11, 2021. The Company has submitted its applications to Bombay Stock Exchange.
- 9 The accumulated losses at ₹ 1,709.92 lakhs (including loss of ₹ 193.58 lakhs for the quarter and ₹ 1,300.38 lakhs for the year ended March 31, 2022, respectively) in Fermenta Biotech GmbH, wholly owned subsidiary (WOS) of the Parent Company at Germany exceed the equity share capital. The WOS was incorporated fairly recently on June 14, 2019 and there has been considerable delay in obtaining the required approvals to execute sales for procedural reasons in view of the global pandemic "Covid-19". The WOS had obtained the required approvals in the previous quarter, and commenced sales of its products. The management of the Company is of the view that these losses have been incurred in view of the unusual circumstances explained and are temporary in nature. The WOS expects to gradually recoup the losses.
- 10 The figures for the quarter ended March 31, 2022 and March 31, 2021 are the balancing figures between the audited figures in respect of the full financial year ended March 31, 2022 and March 31, 2021 and the unaudited published year to date figures upto the nine months ended December 31, 2021 and December 31, 2020 of the relevant financial year which were subject to limited review by the statutory auditors.
- 11 The Board of Directors at their meeting held on May 30, 2022 have proposed a dividend of 25 % ( ₹ 1.25 per share) for the financial year ended 2021-2022. The payment of dividend is subject to approval of shareholders in the ensuing Annual General Meeting.



Place: Thane  
May 30, 2022



Krishna Datla  
Executive-Vice Chairman